HKD 26.85
(-1.65%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 438.37 Million CNY | 98.31% |
2022 | 258.66 Million CNY | -32.72% |
2021 | 384.43 Million CNY | 47.54% |
2020 | 260.56 Million CNY | -40.51% |
2019 | 437.96 Million CNY | -1.16% |
2018 | 443.12 Million CNY | 6.64% |
2017 | 415.51 Million CNY | 11.43% |
2016 | 372.9 Million CNY | 16.04% |
2015 | 321.35 Million CNY | 47.27% |
2014 | 218.21 Million CNY | 52.82% |
2013 | 142.79 Million CNY | 13.48% |
2012 | 125.83 Million CNY | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | 114.42 Million CNY | -2.08% |
2024 Q2 | 148.36 Million CNY | 29.66% |
2023 Q2 | 101.72 Million CNY | -8.58% |
2023 Q3 | 138.92 Million CNY | 36.57% |
2023 Q4 | 116.85 Million CNY | -15.89% |
2023 Q1 | 111.26 Million CNY | 502.64% |
2023 FY | 512.95 Million CNY | 98.31% |
2022 FY | 258.66 Million CNY | -32.72% |
2022 Q4 | 18.46 Million CNY | -85.97% |
2022 Q3 | 131.58 Million CNY | 338.38% |
2022 Q2 | 30.01 Million CNY | 0.0% |
2022 Q1 | 30.01 Million CNY | 200.12% |
2021 Q1 | 94.83 Million CNY | 7.9% |
2021 Q3 | 35.47 Million CNY | -62.59% |
2021 Q4 | -29.97 Million CNY | -184.49% |
2021 FY | 384.43 Million CNY | 47.54% |
2021 Q2 | 94.83 Million CNY | 0.0% |
2020 Q4 | 87.89 Million CNY | 25.75% |
2020 FY | 260.56 Million CNY | -40.51% |
2020 Q1 | -73.02 Million CNY | -337.69% |
2020 Q2 | 8.07 Million CNY | 111.06% |
2020 Q3 | 69.89 Million CNY | 765.37% |
2019 Q3 | 70.75 Million CNY | -44.3% |
2019 Q2 | 127.02 Million CNY | 72.11% |
2019 FY | 437.96 Million CNY | -1.16% |
2019 Q1 | 73.8 Million CNY | -16.69% |
2019 Q4 | 30.72 Million CNY | -56.57% |
2018 Q1 | 100.74 Million CNY | -2.0% |
2018 FY | 443.12 Million CNY | 6.64% |
2018 Q4 | 88.59 Million CNY | 0.0% |
2018 Q3 | 88.59 Million CNY | -12.06% |
2018 Q2 | 100.74 Million CNY | 0.0% |
2017 FY | 415.51 Million CNY | 11.43% |
2017 Q1 | 83.3 Million CNY | 11.45% |
2017 Q2 | 83.3 Million CNY | 0.0% |
2017 Q3 | 102.8 Million CNY | 23.4% |
2017 Q4 | 102.8 Million CNY | 0.0% |
2016 Q2 | 67.45 Million CNY | 0.0% |
2016 FY | 372.9 Million CNY | 16.04% |
2016 Q3 | 74.75 Million CNY | 10.82% |
2016 Q1 | 67.45 Million CNY | 48.52% |
2016 Q4 | 74.75 Million CNY | 0.0% |
2015 Q2 | 65.88 Million CNY | 0.0% |
2015 Q4 | 45.41 Million CNY | 0.0% |
2015 FY | 321.35 Million CNY | 47.27% |
2015 Q1 | 65.88 Million CNY | 31.37% |
2015 Q3 | 45.41 Million CNY | -31.07% |
2014 Q1 | 43.56 Million CNY | 28.76% |
2014 Q4 | 50.15 Million CNY | 0.0% |
2014 FY | 218.21 Million CNY | 52.82% |
2014 Q3 | 50.15 Million CNY | 15.12% |
2014 Q2 | 43.56 Million CNY | 0.0% |
2013 Q4 | 33.83 Million CNY | 0.0% |
2013 Q1 | 37.55 Million CNY | 0.0% |
2013 FY | 142.79 Million CNY | 13.48% |
2013 Q3 | 33.83 Million CNY | -9.91% |
2013 Q2 | 37.55 Million CNY | 0.0% |
2012 FY | 125.83 Million CNY | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Uni-Bio Science Group Limited | 67.76 Million HKD | -546.879% |
CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 51.18% |